Nouscom bets on dual vaccine strategy to outsmart cancer

This week on The Pharma Letter Podcast, we’re joined by Marina Udier, chief executive of Nouscom — a biotech company developing cancer vaccines.

Founded in 2015, the firm is working on cancer vaccines that use a viral vector platform to train the immune system to recognize and attack cancer. The company is developing both personalized and off-the-shelf approaches, aiming to treat a range of tumors.

Before taking the helm at Nouscom, Dr Udier built a diverse career across healthcare — working in consulting, big pharma, and venture capital. That breadth of experience now informs her leadership at a company with big ambitions in oncology.

With more than $80 million in new funding and a partnership in place with Janssen, the company is focused on moving its vaccines further through clinical development.

Earlier this year, Nouscom shared data at the annual AACR congress from a study in people with Lynch Syndrome — a genetic condition that increases the risk of certain cancers.

In this episode, we’ll ask Dr Udier about the latest results, how partnerships fit into the company’s strategy, and why cancer prevention may play a bigger role in the future of oncology.